Express Pharma

Cipla receives final approval for Medroxyprogesterone Injectable


The drug, a progestin, is indicated for the prevention of pregnancy

Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Medroxyprogesterone Injectable, 150mg/mL from the United States Food and Drug Administration (US FDA).

Cipla’s Medroxyprogesterone Injectable, 150mg/mL is AB-rated generic therapeutic equivalent version of Pfizer’s Depo-Provera. It is a progestin indicated only for the prevention of pregnancy. According to IQVIA (IMS Health), Depo-Provera and its generic equivalents had US sales of approximately $159 million for the 12-month period ending November 2018.



Comments are closed.